On myocardial siderosis and left ventricular dysfunction in hemochromatosis

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Carpenter, John Paul ^a,b   Grasso, Agata E ^a   Porter, John B ^c   Shah, Farrukh ^d,e   Dooley, James ^e   Pennell, Dudley J ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d WHITTINGTON HOSPITAL   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiomyopathy; Heart; Heart failure; Hemochromatosis; Iron overload; Magnetic resonance

Indexed keywords

FERRITIN; IRON;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENOTYPE; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOCHROMATOSIS; HOMOZYGOSITY; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; MALE; PHLEBOTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; FERRITINS; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HEMOCHROMATOSIS; HEMOSIDEROSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIUM; PHENOTYPE; PHLEBOTOMY; PROSPECTIVE STUDIES; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84875026585     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-24     Document Type: Article

References (43)

1. Hereditary haemochromatosis. Limdi JK, Crampton JR, QJM 2004 97 315 324 15152104 (Pubitemid 38807410)
2. EASL clinical practice guidelines for HFE hemochromatosis. European Association For The Study Of The Liver, J Hepatol 2010 53 3 22 10.1016/j.jhep.2010.03.001 20471131
3. Hereditary hemochromatosis gene (HFE) mutations C282Y, H63D and S65C in patients with idiopathic dilated cardiomyopathy. Hannuksela J, Leppilampi M, Peuhkurinen K, Eur J Heart Fail 2005 7 103 108 10.1016/j.ejheart.2004.03.007 15642540 (Pubitemid 40092500)
4. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Hanson EH, Imperatore G, Burke W, Am J Epidemiol 2001 154 193 206 10.1093/aje/154.3.193 11479183 (Pubitemid 32701154)
5. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR, Ann Intern Med 2006 145 209 223 16880463 (Pubitemid 46780566)
6. Penetrance of 845G A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T, Lancet 2002 359 211 218 10.1016/S0140-6736(02)07447-0 11812557 (Pubitemid 34113819)
7. Iron-overload-related disease in HFE hereditary hemochromatosis. Allen KJ, Gurrin LC, Constantine CC, N Engl J Med 2008 358 221 230 10.1056/NEJMoa073286 18199861
8. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Wood MJ, Powell LW, Ramm GA, Blood 2008 111 4456 4462 10.1182/blood-2007-11-122374 18316631
9. Genetic mechanisms and modifying factors in hereditary hemochromatosis. Weiss G, Nat Rev Gastroenterol Hepatol 2010 7 50 58 10.1038/nrgastro.2009.201 19918260
10. HFE-associated hereditary hemochromatosis. Alexander J, Kowdley KV, Genet Med 2009 11 307 313 10.1097/GIM.0b013e31819d30f2 19444013
11. Diagnosis and management of hereditary haemochromatosis. Van Bokhoven MA, Van Deursen CT, Swinkels DW, Br Med J 2011 342 218 223
12. Cardiac hemochromatosis. Templin C, Pertschy S, Schaefer A, Int J Cardiol 2007 116 109 e110 10.1016/j.ijcard.2006.08.102 17134777 (Pubitemid 46283040)
13. Multi-center transferability of a breath-hold T2 technique for myocardial iron assessment. He T, Kirk P, Firmin DN, J Cardiovasc Magn Reson 2008 10 11 10.1186/1532-429X-10-11 18291040
14. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
15. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Wood JC, Otto-Duessel M, Aguilar M, Circulation 2005 112 535 543 10.1161/CIRCULATIONAHA.104.504415 16027257 (Pubitemid 41060794)
16. On T2* magnetic resonance and cardiac iron. Carpenter JP, He T, Kirk P, Circulation 2011 123 1519 1528 10.1161/CIRCULATIONAHA.110.007641 21444881
17. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Kirk P, Roughton M, Porter JB, Circulation 2009 120 1961 1968 10.1161/CIRCULATIONAHA.109.874487 19801505
18. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Tanner MA, Galanello R, Dessi C, J Cardiovasc Magn Reson 2008 10 12 10.1186/1532-429X-10-12 18298856
19. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ, J Am Coll Cardiol 1987 10 1239 1243 10.1016/S0735-1097(87) 80124-9 3680791 (Pubitemid 18004674)
20. Diagnosis and management of hemochromatosis. Tavill AS, Hepatology 2001 33 1321 1328 10.1053/jhep.2001.24783 11343262 (Pubitemid 32378233)
21. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. Westwood M, Anderson LJ, Firmin DN, J Magn Reson Imaging 2003 18 33 39 10.1002/jmri.10332 12815637 (Pubitemid 36791266)
22. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. Maceira AM, Prasad SK, Khan M, Pennell DJ, J Cardiovasc Magn Reson 2006 8 417 426 10.1080/ 10976640600572889 16755827
23. Myocardial T2* measurement in iron-overloaded thalassemia: an ex vivo study to investigate optimal methods of quantification. He T, Gatehouse PD, Kirk P, Mohiaddin RH, Pennell DJ, Firmin DN, Magn Reson Med 2008 60 350 356 10.1002/mrm.21625 18666131
24. Myocardial T2* measurements in iron-overloaded thalassemia: An in vivo study to investigate optimal methods of quantification. He T, Gatehouse PD, Smith GC, Mohiaddin RH, Pennell DJ, Firmin DN, Magn Reson Med 2008 60 1082 1089 10.1002/mrm.21744 18956471
25. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Grothues F, Smith GC, Moon JC, Am J Cardiol 2002 90 29 34 10.1016/S0002-9149(02)02381-0 12088775 (Pubitemid 34671198)
26. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Wood JC, Enriquez C, Ghugre N, Blood 2005 106 1460 1465 10.1182/blood-2004-10-3982 15860670 (Pubitemid 41129616)
27. Hereditary hemochromatosis-a new look at an old disease. Pietrangelo A, N Engl J Med 2004 350 2383 2397 10.1056/NEJMra031573 15175440 (Pubitemid 38702849)
28. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Goland S, Beilinson N, Kaftouri A, Shimoni S, Caspi A, Malnick SD, Eur J Heart Fail 2004 6 547 550 15302000 (Pubitemid 39070506)
29. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Anderson LJ, Westwood MA, Holden S, Br J Haematol 2004 127 348 355 10.1111/j.1365-2141.2004.05202.x 15491298 (Pubitemid 39468951)
30. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell DJ, Berdoukas V, Karagiorga M, Blood 2006 107 3738 3744 10.1182/blood-2005-07- 2948 16352815
31. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA, Galanello R, Dessi C, Circulation 2007 115 1876 1884 10.1161/CIRCULATIONAHA.106.648790 17372174 (Pubitemid 46598901)
32. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R, Circulation 1992 86 803 811 10.1161/01.CIR.86.3.803 1516192
33. Stored iron and ischemic heart disease. Empirical support for a new paradigm. Sullivan JL, Circulation 1992 86 1036 1037 10.1161/01.CIR.86.3.1036 1516175
34. Iron stores are not associated with acute myocardial infarction. Baer DM, Tekawa IS, Hurley LB, Circulation 1994 89 2915 2918 10.1161/01.CIR.89.6.2915 8205708 (Pubitemid 24173715)
35. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH, Atherosclerosis 2001 154 739 746 10.1016/S0021-9150(00)00623-7 11257277 (Pubitemid 32232173)
36. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Roest M, van der Schouw YT, De Valk B, Circulation 1999 100 1268 1273 10.1161/01.CIR.100.12.1268 10491369 (Pubitemid 29440117)
37. Haemochromatosis gene mutations in idiopathic dilated cardiomyopathy. Mahon NG, Coonar AS, Jeffery S, Heart 2000 84 541 547 10.1136/heart.84.5.541 11040018
38. Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study. Hetet G, Grandchamp B, Bouchier C, CARDIGENE Group, Heart 2001 86 702 703 10.1136/heart.86.6.702 11711473 (Pubitemid 33086895)
39. Idiopathic dilated cardiomyopathy: familial prevalence and HLA distribution. McKenna CJ, Codd MB, McCann HA, Sugrue DD, Heart 1997 77 549 552 9227300 (Pubitemid 27294695)
40. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. Mestroni L, Rocco C, Gregori D, J Am Coll Cardiol 1999 34 181 190 10.1016/S0735-1097(99)00172-2 10400009
41. Decreased CD8-p56lck activity in peripheral blood T-lymphocytes from patients with hereditary haemochromatosis. Arosa FA, Da Silva AJ, Godinho IM, Scand J Immunol 1994 39 426 432 10.1111/j.1365-3083.1994.tb03396.x 8191217 (Pubitemid 24227764)
42. Revisiting the relationship between vitamin D deficiency, cardiac iron and cardiac function in thalassemia major. Noetzli LJ, Carson S, Coates TD, Wood JC, Eur J Haematol 2011 86 176 177 10.1111/j.1600-0609.2010.01538.x 20942841
43. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Claster S, Wood JC, Noetzli L, Am J Hematol 2009 84 344 348 10.1002/ajh.21416 19415722